Compounded semaglutide and tirzepatide became widely available between 2022 and 2024 after Ozempic, Wegovy, Mounjaro, and Zepbound landed on the FDA's official drug shortage list. Under federal law, state-licensed 503A pharmacies and 503B outsourcing facilities may compound a copy of an FDA-approved drug from bulk active ingredient only while that drug is in shortage or the compounded version is not essentially a copy of a commercially available product. Telehealth companies built entire businesses around $150 to $400 per month compounded vials, roughly a third of the $1,000-plus brand retail price, and millions of patients used them.
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Enforcement discretion for 503A pharmacies ended March 13, 2025 for tirzepatide and April 22, 2025 for semaglutide; 503B outsourcing facilities lost discretion by May 22, 2025. That legal deadline forced most mass-market compounders to stop selling copies of Ozempic, Wegovy, Mounjaro, and Zepbound. The clearest example came in February 2026, when Hims & Hers launched a $49 per month compounded semaglutide pill, drew an FDA warning within two days, faced a Novo Nordisk patent-infringement lawsuit, and pulled the product from its platform before the week ended.
In April 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would bar outsourcing facilities from compounding these drugs from bulk substances even without a shortage; the public comment period closed in mid-2026 and a final rule is pending. Narrow 503A patient-specific compounding still exists for documented medical need, such as an allergy to an inactive ingredient, but pharmacies cannot compound it regularly or in inordinate amounts if it duplicates a commercial product. Meanwhile, the Inflation Reduction Act's Maximum Fair Price provision adds semaglutide products (Ozempic, Wegovy, Rybelsus) to Medicare's second round of drug price negotiation, effective January 2027; tirzepatide has not yet been selected for negotiation.
What Compounded GLP-1 Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same compounded glp-1 can cost many times more at a hospital than at your local pharmacy:
2026 Compounded GLP-1 Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Legitimate compounded (503A, patient-specific, 2026) | $229 - $549/month | Rare in 2026; requires documented medical necessity, not a shortage-based copy |
| Manufacturer direct-pay (NovoCare Pharmacy / LillyDirect) | $199 - $449/month | No insurance or income requirement; the main replacement for discontinued compounding |
| Medicare Part D / GLP-1 Bridge (2026) | $0 - $50/month, or standard formulary tier for diabetes use | Bridge covers Wegovy/Zepbound/Foundayo for obesity from July 1, 2026 through 2027 |
| Commercial insurance (brand, with prior authorization) | $25 - $300/month | Depends on formulary tier and whether weight-loss indication is covered at all |
| Pharmacy counter cash (brand, no discount) | $1,000 - $1,349/month | The price patients now face without a compounded or direct-pay option |
Prices reflect 2026 manufacturer, GoodRx, and telehealth listings. Compounded prices vary by pharmacy, dose, and state; verify a compounder's 503A license before paying.
Source: FDA compounding policy statements, CMS Medicare GLP-1 Bridge program, NovoCare, LillyDirect, GoodRx
Why Hospitals Charge So Much
Emergency departments, not inpatient wards, are where compounded GLP-1 costs most often surface on a hospital bill. The FDA logged more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many involving dosing errors from patients drawing the wrong volume out of a multidose vial measured in milliliters instead of milligrams. An ER visit for a resulting overdose, nausea, or pancreatitis workup routinely runs $1,800 to $4,200 once facility fees, imaging, and IV fluids are added, far more than the drug itself ever cost.
Facility charges climb further when a patient cannot identify what was actually injected. Unlike FDA-approved pens with a fixed National Drug Code, compounded vials often carry a pharmacy-specific label, and some products used alternate salt forms (semaglutide sodium or semaglutide acetate) that the FDA flagged as not equivalent to the approved active ingredient. Ask the ER or your pharmacy for the compounding pharmacy's name, license number, and exact formulation before the bill is coded, since insurers and Medicare routinely deny claims tied to non-FDA-approved products, shifting the full charge to the patient.
Patient Assistance Programs
With mass-market compounding largely closed off, the manufacturers' own programs are now the primary route to an affordable price. Novo Nordisk runs NovoCare for Ozempic, Wegovy, and Rybelsus; Eli Lilly runs Lilly Cares and LillyDirect for Mounjaro and Zepbound. Eligibility and coverage differ sharply between the diabetes-labeled and weight-loss-labeled versions of each drug.
Patient assistance programs for Compounded GLP-1| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Novo Nordisk NovoCare Patient Assistance Program (PAP) | Free Ozempic for uninsured patients with type 2 diabetes at or below 400% FPL; Wegovy PAP eligibility is narrower and BMI-dependent | novocare.com/pap |
| Lilly Cares Foundation | Free Mounjaro for uninsured patients with type 2 diabetes at or below 400% FPL; Zepbound is not currently on the Lilly Cares formulary | lillycares.com |
| NovoCare Pharmacy (Wegovy self-pay vial) | $199/month for the two starting doses, $349/month flat for all other doses, no income requirement | novocarepharmacy.com |
| LillyDirect Self Pay Journey Program (Zepbound / Mounjaro self-pay vial) | $299 - $449/month for Zepbound by dose; $499/month flat for Mounjaro, no income requirement | lillydirect.lilly.com |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies for brand GLP-1 prescriptions | needymeds.org |
Manufacturer coupons and savings cards for Wegovy, Zepbound, Ozempic, and Mounjaro cannot legally be used by anyone with Medicare, Medicaid, TRICARE, or VA coverage under the federal anti-kickback statute (42 U.S.C. § 1320a-7b). Government-insured patients should apply for the manufacturer patient assistance program or the Medicare GLP-1 Bridge program instead.
Source: Novo Nordisk NovoCare, Eli Lilly Lilly Cares and LillyDirect, NeedyMeds.org
Medicare Part D
Medicare Part D covers Ozempic and Mounjaro when prescribed for type 2 diabetes, and your copay depends on your plan's formulary tier. Total out-of-pocket spending across all Part D drugs combined is capped at $2,100 for 2026 under the Inflation Reduction Act. Medicare has never covered, and does not cover, compounded copies of these drugs regardless of price, because Part D only reimburses FDA-approved products dispensed under their approved labeling.
The Medicare GLP-1 Bridge program, launched July 1, 2026, extends coverage to Wegovy, Zepbound, and Foundayo for obesity at a flat $50 monthly copay for beneficiaries who meet one of three BMI pathways (35+, or 30+ with a qualifying condition, or 27+ with a qualifying condition). That $50 copay does not count toward the $2,100 annual cap, and Medicare Extra Help cost-sharing does not apply to it. The Bridge program runs through December 31, 2027 and is the closest legal substitute Medicare beneficiaries have for the cheap compounded weight-loss vials that disappeared in 2025.
Patients who relied on compounded vials before 2025 and are now moving to a Part D plan should confirm the drug's formulary tier and whether prior authorization is required before their first fill, since diabetes-labeled Ozempic and Mounjaro face different rules than weight-loss-labeled Wegovy and Zepbound even though the molecules are identical.
Common Compounded GLP-1 Billing Errors
If you got billed more than expected for a compounded or brand GLP-1 in 2026, check for these issues before paying:
- Insurance or Medicare claim denied outright because the product dispensed was a compounded copy, not the FDA-approved brand. Part D and most commercial plans never reimburse compounded semaglutide or tirzepatide, leaving the patient responsible for the full cash price.
- A different salt form, such as semaglutide sodium or semaglutide acetate, dispensed and billed at the same price as the FDA-approved base compound without disclosure. The FDA specifically warned that these salt forms are not the same active ingredient as approved Ozempic or Wegovy.
- A telehealth platform's separate monthly membership or consultation fee stacked on top of the advertised drug price, pushing the real monthly cost well above the number in the ad.
- Prepaid subscription doses never delivered after a compounding pharmacy abruptly shut down or stopped selling GLP-1 products following FDA enforcement, with no automatic refund issued.
- A manufacturer savings card rejected at the pharmacy counter because it was mistakenly applied to a compounded product; savings cards only work on the FDA-approved brand product they were issued for.
Frequently Asked Questions
Is compounded semaglutide or tirzepatide still legal in 2026?
Narrowly, yes, but the door has mostly closed. State-licensed 503A pharmacies can still compound semaglutide or tirzepatide for an individual patient with a documented medical need, such as an allergy to an inactive ingredient, but not as a routine, high-volume copy of Ozempic, Wegovy, Mounjaro, or Zepbound. The FDA ended shortage-based compounding discretion by May 2025 and proposed in April 2026 to permanently bar 503B outsourcing facilities from bulk-compounding these drugs at all. Mass-market telehealth compounding, the $150-$400/month model most patients used from 2022-2024, is effectively over.
What does compounded GLP-1 cost in 2026 now that most compounders have stopped selling it?
Legitimate 503A patient-specific compounded semaglutide or tirzepatide costs roughly $229 to $549 per month in 2026, but it is rare and requires documented medical necessity. Most patients priced out of the old shortage-era compounding now pay $199 to $449 per month through manufacturer direct-pay vial programs, NovoCare Pharmacy for Wegovy or LillyDirect for Zepbound, instead. Full brand retail cash price without any discount runs $1,000 to $1,349 per month.
Is there a generic for Ozempic, Wegovy, Mounjaro, or Zepbound?
No. There is no FDA-approved generic or biosimilar for semaglutide or tirzepatide as of 2026; both remain patent-protected through the early-to-mid 2030s. Because these are synthetic peptides rather than large therapeutic proteins, they would eventually follow a generic drug pathway, not the biosimilar pathway used for biologics like Humira. Compounded versions sold by pharmacies are not FDA-approved generics; they are unapproved copies, which is exactly why the FDA is shutting most of them down.
How do I apply for the NovoCare or Lilly Cares patient assistance program?
Start at novocare.com/pap for Ozempic or Wegovy, or lillycares.com for Mounjaro. Download the patient assistance program application, complete the patient section, and have your prescriber complete the clinical section. Submit proof of household income, proof of US residency, your prescription, and a statement that you lack prescription drug coverage for the drug. Approval typically takes 10 to 15 business days, and free medication ships directly to you or your prescriber; renewal is required every 12 months.
Can I use a manufacturer savings card for Wegovy or Zepbound with Medicare?
No. Federal anti-kickback law bars anyone on Medicare, Medicaid, TRICARE, or VA benefits from using a manufacturer coupon or savings card. If you have Medicare, your legal options are the manufacturer's income-based patient assistance program, or, for weight loss specifically, the new Medicare GLP-1 Bridge program launched July 1, 2026, which caps Wegovy, Zepbound, and Foundayo at $50 per month for eligible beneficiaries through 2027.
What if my insurance denies coverage for a GLP-1 drug?
Request the written denial notice and file a formal appeal within your plan's deadline, usually 60 days. Ask your prescriber to submit a peer-to-peer review citing your diagnosis and BMI, and request a step therapy override if your plan requires you to fail a cheaper drug first. If the appeal fails, apply for the manufacturer's patient assistance program or price the drug through NovoCare Pharmacy or LillyDirect self-pay, both of which run well below full retail without insurance.
Does the Inflation Reduction Act's Maximum Fair Price apply to Ozempic, Wegovy, or Zepbound?
Not yet, but it is coming for semaglutide. Semaglutide products (Ozempic, Wegovy, Rybelsus) were selected for Medicare's second round of drug price negotiation under the Inflation Reduction Act, with a negotiated Maximum Fair Price taking effect January 1, 2027. Tirzepatide (Mounjaro, Zepbound) has not been selected for negotiation in any round so far. Until 2027, semaglutide pricing on Medicare follows standard Part D formulary rules, not a negotiated rate.
Do I qualify for the NovoCare or Lilly Cares patient assistance program?
Both programs generally require US residency, a valid prescription, no prescription drug coverage for the drug (or a documented denial), and household income at or below 400% of the federal poverty level, about $63,840 for a household of one or $132,000 for a household of four in 2026. Coverage differs by drug: Ozempic and Mounjaro (diabetes labels) are broadly included, while Wegovy PAP eligibility is narrower and Zepbound is not currently on the Lilly Cares formulary at all.
